Arcede Pharma, which just released its first quarterly report as a separately listed company, presented at the BioStock Investor Meeting in September. In connection with the event, BioStock took the opportunity to interview the company’s CEO Mia Lundblad regarding drug candidate RCD405. The candidate, which is developed to treat of COPD and severe asthma, is currently being prepared for clinical phase I.
See the full interview with Arcede Pharma CEO Mia Lundblad below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.